Microfluidic models for adoptive cell-mediated cancer immunotherapies.
暂无分享,去创建一个
J. Thiery | R. Kamm | A. Bertoletti | A. Pavesi | A. Tan | Giulia Adriani
[1] Roger D. Kamm,et al. Engineering a 3D microfluidic culture platform for tumor-treating field application , 2016, Scientific Reports.
[2] Roger D. Kamm,et al. M2a macrophages induce contact-dependent dispersion of carcinoma cell aggregates , 2016 .
[3] H. Zhang,et al. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study , 2016, Tumor Biology.
[4] A. Ribas,et al. Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.
[5] U. Demirci,et al. Engineering cancer microenvironments for in vitro 3-D tumor models , 2015, Materials today.
[6] A. Pavesi,et al. Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[7] R. Duarte,et al. Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. , 2015, Journal of immunological methods.
[8] Wendell A. Lim,et al. Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.
[9] Roger D. Kamm,et al. Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment , 2015, Oncotarget.
[10] J. Thiery,et al. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions , 2015, Oncotarget.
[11] Shuichi Takayama,et al. Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays. , 2015, Gynecologic oncology.
[12] R. Childs,et al. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.
[13] H. Tawbi,et al. Immunotherapeutic Approaches to Sarcoma , 2015, Current Treatment Options in Oncology.
[14] K. Barbee,et al. An in vitro model of the tumor-lymphatic microenvironment with simultaneous transendothelial and luminal flows reveals mechanisms of flow enhanced invasion. , 2015, Integrative biology : quantitative biosciences from nano to macro.
[15] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[16] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[17] R. Kamm,et al. G04 : Engineered HBV-specific T cells: Disentangling antiviral from killing capacity , 2015 .
[18] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[20] T. Curiel,et al. Immunotherapy for Ovarian Cancer , 2015, Current Treatment Options in Oncology.
[21] A. Bertoletti,et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.
[22] Henry Du,et al. Evaluation of photodynamic therapy efficiency using an in vitro three-dimensional microfluidic breast cancer tissue model. , 2015, Lab on a chip.
[23] D. Beebe,et al. Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure , 2015, BMC Cancer.
[24] G. Dubini,et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation , 2014, Proceedings of the National Academy of Sciences.
[25] C. Morrison. Developers seek to finetune toxicity of T-cell therapies , 2014, Nature Biotechnology.
[26] J. Clements,et al. 3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer , 2014, PloS one.
[27] Roger D Kamm,et al. A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. , 2014, Lab on a chip.
[28] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[29] Lidong Qin,et al. High-Throughput 3D Cell Invasion Chip Enables Accurate Cancer Metastatic Assays , 2014, Journal of the American Chemical Society.
[30] F. Belardelli,et al. A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells , 2014, Journal of immunotoxicology.
[31] Noo Li Jeon,et al. A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation. , 2014, Biomicrofluidics.
[32] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[33] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[34] D. Beebe,et al. The present and future role of microfluidics in biomedical research , 2014, Nature.
[35] P. Wong,et al. A microfluidic model for organ-specific extravasation of circulating tumor cells. , 2014, Biomicrofluidics.
[36] G. Dubini,et al. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. , 2014, Biomaterials.
[37] R. Huang,et al. Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. , 2014, Biomaterials.
[38] D. Siegel,et al. Patient-specific 3D microfluidic tissue model for multiple myeloma. , 2014, Tissue engineering. Part C, Methods.
[39] H. Abken,et al. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma , 2014, Immunological reviews.
[40] Harjeet Singh,et al. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.
[41] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[42] M. Raghunath,et al. Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[43] David J. Beebe,et al. Understanding the Impact of 2D and 3D Fibroblast Cultures on In Vitro Breast Cancer Models , 2013, PloS one.
[44] A. Stroock,et al. Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. , 2013, Journal of biomedical materials research. Part A.
[45] K. Eliceiri,et al. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. , 2013, Lab on a chip.
[46] F. Rico,et al. Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro , 2013, Proceedings of the National Academy of Sciences of the United States of America.
[47] Roger D. Kamm,et al. Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening , 2013, Advanced healthcare materials.
[48] R. Kamm,et al. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[49] D. Campana,et al. A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.
[50] M. Kalos,et al. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.
[51] B. Shalmon,et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.
[52] Stephen J. Florczyk,et al. Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. , 2013, Biomacromolecules.
[53] R. Jain. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[55] C. Regenbrecht,et al. Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? , 2013, Clinical & Experimental Metastasis.
[56] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[57] R. Huang,et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[58] Roger D. Kamm,et al. Engineering of In Vitro 3D Capillary Beds by Self-Directed Angiogenic Sprouting , 2012, PloS one.
[59] Stephen J. Florczyk,et al. 3D Porous Chitosan–Alginate Scaffolds: A New Matrix for Studying Prostate Cancer Cell–Lymphocyte Interactions In Vitro , 2012, Advanced healthcare materials.
[60] R. Kamm,et al. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function , 2012, Proceedings of the National Academy of Sciences.
[61] Jianhua Qin,et al. A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime. , 2012, Lab on a chip.
[62] M. Sadelain,et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.
[63] C. Payne,et al. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[64] S. Rosenberg,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[65] Jian-Long Xiao,et al. The migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. , 2012, Integrative biology : quantitative biosciences from nano to macro.
[66] A. Bertoletti,et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.
[67] Stephen-Mark Cooper,et al. The effects of time and intensity of exercise on novel and established markers of CVD in adolescent youth , 2011, American journal of human biology : the official journal of the Human Biology Council.
[68] Francis Lin,et al. Combinatorial Guidance by CCR7 Ligands for T Lymphocytes Migration in Co-Existing Chemokine Fields , 2011, PloS one.
[69] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[70] K. Pienta,et al. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. , 2009, Biomaterials.
[71] Ivan Martin,et al. New dimensions in tumor immunology: what does 3D culture reveal? , 2008, Trends in molecular medicine.
[72] J. Aerts,et al. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics , 2007, Gene Therapy.
[73] L. Terracciano,et al. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes , 2007, British Journal of Cancer.
[74] H. Levitsky,et al. Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance1 , 2007, The Journal of Immunology.
[75] O. Singer,et al. Use of Amplicon-6 Vectors Derived from Human Herpesvirus 6 for Efficient Expression of Membrane-Associated and -Secreted Proteins in T Cells , 2004, Journal of Virology.
[76] A. Lawson,et al. Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.
[77] Martin Fussenegger,et al. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.
[78] Pierre Validire,et al. Impact of human bladder cancer cell architecture on autologous T‐lymphocyte activation , 2002, International journal of cancer.
[79] A. Mikos,et al. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. , 2016, Biomaterials.
[80] Z. Ren,et al. Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. , 2014, International journal of clinical and experimental pathology.
[81] R. Brentjens. with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults , 2013 .